Verschlimmbesserung: Craniospinal Radiotherapy is Essential in WNT Medulloblastoma Patients.
Nicholas G GottardoAmar J GajjarPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Standard-risk WNT medulloblastoma patients have an excellent prognosis (>90% progression free survival) using the combination of standard dose craniospinal radiotherapy (CSI) (23.4Gy) followed by platinum and alkylator based chemotherapy. A recent pilot study which attempted to completely omit radiotherapy was terminated early as all patients (n=3) relapsed rapidly (on treatment or within 6 months of completing treatment). The study highlights that therapy is the most important prognostic factor, with CSI still required to cure even the most favorable subgroup of medulloblastoma patients.
Keyphrases
- prognostic factors
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- early stage
- stem cells
- radiation therapy
- cell proliferation
- randomized controlled trial
- squamous cell carcinoma
- locally advanced
- radiation induced
- patient reported outcomes
- multiple myeloma
- diffuse large b cell lymphoma
- hodgkin lymphoma
- combination therapy
- cell therapy
- rectal cancer
- open label